|
1
|
Scholzen T and Gerdes J: The Ki-67
protein: from the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shirendeb U, Hishikawa Y, Moriyama S, et
al: Human papillomavirus infection and its possible correlation
with p63 expression in cervical cancer in Japan, Mongolia, and
Myanmar. Acta Histochem Cytochem. 42:181–190. 2009. View Article : Google Scholar
|
|
3
|
Hooghe B, Hulpiau P, Van Roy F and De
Bleser PD: ConTra: a promoter alignment analysis tool for
identification of transcription factor binding sites across
species. Nucleic Acids Res. 36:W128–W132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Modlin IM, Moss SF, Chung DC, et al:
Priorities for improving the management of gastroenteropancreatic
neuroendocrine tumors. J Natl Cancer Inst. 100:1282–1289. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Klöppel G, Perren A and Heitz PU: The
gastroenteropancreatic neuroendocrine cell system and its tumors:
the WHO classification. Ann N Y Acad Sci. 1014:13–27. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brown DC and Gatter KC: Ki67 protein: the
immaculate deception? Histopathology. 40:2–11. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishihara M, Mukai H, Nagai S, et al:
Retrospective analysis of risk factors for central nervous system
metastases in operable breast cancer: effects of biologic subtype
and Ki67 overexpression on survival. Oncology. 84:135–140. 2013.
View Article : Google Scholar
|
|
8
|
Sorbye SW, Kilvaer TK, Valkov A, et al:
Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft
tissue sarcomas. PLoS One. 7:e470682012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sorbye SW, Kilvaer TK, Valkov A, et al:
Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta
in soft tissue sarcomas. BMC Clin Pathol. 12:72012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ciancio N, Galasso MG, Campisi R, et al:
Prognostic value of p53 and Ki67 expression in fiberoptic bronchial
biopsies of patients with non small cell lung cancer. Multidiscip
Respir Med. 7:292012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Josefsson A, Wikström P, Egevad L, et al:
Low endoglin vascular density and Ki67 index in Gleason score 6
tumours may identify prostate cancer patients suitable for
surveillance. Scand J Urol Nephrol. 46:247–257. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iatropoulos MJ and Williams GM:
Proliferation markers. Exp Toxicol Pathol. 48:175–181. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jacquemier JD, Penault-Llorca FM, Bertucci
F, et al: Angiogenesis as a prognostic marker in breast carcinoma
with conventional adjuvant chemotherapy: a multiparametric and
immunohistochemical analysis. J Pathol. 184:130–135. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kausch I, Lingnau A, Endl E, et al:
Antisense treatment against Ki-67 mRNA inhibits proliferation and
tumor growth in vitro and in vivo. Int J Cancer. 105:710–716. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J, Fang L, Cheng Q, et al: Effects of
G250 promoter controlled conditionally replicative adenovirus
expressing Ki67-siRNA on renal cancer cell. Cancer Sci.
103:1880–1888. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gerlach C, Sakkab DY, Scholzen T, et al:
Ki-67 expression during rat liver regeneration after partial
hepatectomy. Hepatology. 26:573–578. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Le Guellec S, Perallon R, Alunni JP, et
al: Neoadjuvant treatment of breast cancer: implications for the
pathologist. Ann Pathol. 31:442–454. 2011.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yerushalmi R, Woods R, Ravdin PM, et al:
Ki67 in breast cancer: prognostic and predictive potential. Lancet
Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Duchrow M, Schlüter C, Wohlenberg C, et
al: Molecular characterization of the gene locus of the human cell
proliferation-associated nuclear protein defined by monoclonal
antibody Ki-67. Cell Prolif. 29:1–12. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Halm U, Tannapfel A, Breitung B, et al:
Apoptosis and cell proliferation in the
metaplasia-dysplasia-carcinoma-sequence of Barrett’s esophagus.
Hepatogastroenterology. 47:962–966. 2000.PubMed/NCBI
|
|
21
|
Rahmanzadeh R, Hüttmann G, Gerdes J and
Sholzen T: Chromophore-assisted light inactivation of pKi67 leads
to inhibition of ribosomal RNA synthesis. Cell Prolif. 40:422–430.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Castro LA, Elias LS, Oton-Leite AF, et al:
Long-term effects of nifedipine on human gingival epithelium: a
histopathological and immunohistochemical study. J Oral Sci.
52:55–62. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Panteva MT, Salari R, Bhattacharjee M and
Chong LT: Direct observations of shifts in the β-sheet register of
a protein-peptide complex using explicit solvent simulations.
Biophys J. 100:L50–L52. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tian H, Qian GW, Li W, et al: A critical
role of Sp1 transcription factor in regulating the human Ki-67 gene
expression. Tumour Biol. 32:273–283. 2011. View Article : Google Scholar
|
|
25
|
Chen F, Song J, Di J, et al: IRF1
suppresses Ki-67 promoter activity through interfering with Sp1
activation. Tumour Biol. 33:2217–2225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakano T, Ohno T, Ishikawa H, et al:
Current advancement in radiation therapy for uterine cervical
cancer. J Radiat Res. 51:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim BH, Bae YS, Kim SH, et al: Usefulness
of Ki-67 (MIB-1) immunostaining in the diagnosis of pulmonary
sclerosing hemangiomas. APMIS. 121:105–110. 2013. View Article : Google Scholar
|
|
28
|
Steels E, Paesmans M, Berghmans T, et al:
Role of p53 as a prognostic factor for survival in lung cancer: a
systematic review of the literature with a meta-analysis. Eur
Respir J. 18:705–719. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Martin B, Paesmans M, Mascaux C, et al:
Ki-67 expression and patients survival in lung cancer: systematic
review of the literature with meta-analysis. Br J Cancer.
91:2018–2025. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Faes T, Pecceu A, Van Calenbergh S and
Moerman P: Chorangiocarcinoma of the placenta: a case report and
clinical review. Placenta. 33:658–661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Almeida JC, Menezes RP, Kuckelhaus SA,
Bocca AL and Figueiredo F: Prognostic value of morphologic and
clinical parameters in pT2 – pT3 prostate cancer. Int Braz J Urol.
33:662–672. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vaira V, Fedele G, Pyne S, et al:
Preclinical model of organotypic culture for pharmacodynamic
profiling of human tumors. Proc Natl Acad Sci USA. 107:8352–8356.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hofman MS and Hicks RJ: Changing paradigms
with molecular imaging of neuroendocrine tumors. Discov Med.
14:71–81. 2012.PubMed/NCBI
|
|
34
|
Laurinavicius A, Plancoulaine B,
Laurinaviciene A, et al: A methodology to ensure and improve
accuracy of Ki67 labelling index estimation by automated digital
image analysis in breast cancer tissue. Breast Cancer Res.
16:R352014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hayashi Y, Takei H and Kurosumi M: Ki67
immunohistochemical staining: the present situation of diagnostic
criteria. Nihon Rinsho. 7:428–432. 2012.(In Japanese).
|
|
36
|
Zizi-Sermpetzoglou A, Moustou E,
Petrakopoulou N, et al: Atypical polypoid adenomyoma of the uterus.
A case report and a review of the literature. Eur J Gynaecol Oncol.
33:118–121. 2012.PubMed/NCBI
|
|
37
|
Zini L, Porpiglia F and Fassnacht M:
Contemporary management of adrenocortical carcinoma. Eur Urol.
60:1055–1065. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Viale G: Pathological work up of the
primary tumor: getting the proper information out of it. Breast.
20(Suppl 3): S82–S86. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Leong AS and Zhuang Z: The changing role
of pathology in breast cancer diagnosis and treatment.
Pathobiology. 78:99–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ibrahim T, Farolfi A, Scarpi E, et al:
Hormonal receptor, human epidermal growth factor receptor-2, and
Ki67 discordance between primary breast cancer and paired
metastases: Clinical impact. Oncology. 84:150–157. 2013. View Article : Google Scholar
|
|
41
|
Chlebowski RT, Col N, Winer EP, et al;
American Society of Clinical Oncology Breast Cancer Technology
Assessment Working Group. American Society of Clinical Oncology
technology assessment of pharmacologic interventions for breast
cancer risk reduction including tamoxifen, raloxifene, and
aromatase inhibition. J Clin Oncol. 20:3328–3343. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Blancato J, Singh B, Liu A, Liao DJ and
Dickson RB: Correlation of amplification and overexpression of the
c-myc oncogene in high grade breast cancer: FISH, in situ
hybridization and immunohistochemical analysis. Br J Cancer.
90:1612–1619. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jonat W and Arnold N: Is the Ki-67
labelling index ready for clinical use? Ann Oncol. 22:500–502.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sapino A, Marchiò C, Senetta R, et al:
Routine assessment of prognostic factors in breast cancer using a
multicore tissue microarray procedure. Virchows Arch. 449:288–296.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Camp RL, Neumeister V and Rimm DL: A
decade of tissue microarrays: progress in the discovery and
validation of cancer biomarkers. J Clin Oncol. 26:5630–5637. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Konsti J, Lundin M, Joensuu H, et al:
Development and evaluation of a virtual microscopy application for
automated assessment of Ki-67 expression in breast cancer. BMC Clin
Pathol. 11:32011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Klimowicz AC, Bose P, Nakoneshny SC, et
al: Basal Ki67 expression measured by digital image analysis is
optimal for prognostication in oral squamous cell carcinoma. Eur J
Cancer. 48:2166–2174. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sánchez-Navarro I, Gámez-Pozo A,
González-Barón M, et al: Comparison of gene expression profiling by
reverse transcription quantitative PCR between fresh frozen and
formalin-fixed, paraffin-embedded breast cancer tissues.
Biotechniques. 48:389–397. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Farragher SM, Tanney A, Kennedy RD and
Paul Harkin D: RNA expression analysis from formalin fixed paraffin
embedded tissues. Histochem Cell Biol. 130:435–445. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mittempergher L, de Ronde JJ, Nieuwland M,
et al: Gene expression profiles from formalin fixed paraffin
embedded breast cancer tissue are largely comparable to fresh
frozen matched tissue. PLoS One. 6:e171632011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Karamitopoulou E, Perentes E, Tolnay M and
Probst A: Prognostic significance of MIB-1, p53, and bcl-2
immunoreactivity in meningiomas. Hum Pathol. 29:140–145. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Geyer FC, Rodrigues DN, Weigelt B and
Reis-Filho JS: Molecular classification of estrogen
receptor-positive/luminal breast cancers. Adv Anat Pathol.
19:39–53. 2012. View Article : Google Scholar
|
|
53
|
Claudio PP, Zamparelli A, Garcia FU, et
al: Expression of Cell-Cycle-regulated Proteins pRb2/p130, p107,
p27kip1, p53, mdm-2, and Ki-67 (MIB-1) in Prostatic Gland
Adenocarcinoma1. Clin Cancer. 8:1808–15. 2002.
|
|
54
|
Hu HY, Liu H, Zhang JW, et al: Clinical
significance of Smac and Ki-67 expression in pancreatic cancer.
Hepato-gastroenterology. 59:2640–2643. 2012.PubMed/NCBI
|
|
55
|
McCormick D, Chong H, Hobbs C, et al:
Detection of the Ki-67 antigen in fixed and wax-embedded sections
with the monoclonal antibody MIB-1. Histopathology. 22:355–360.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Merkel D, Dresseler L and McGuire WL: Flow
cytometry, cellular DNAcontent, and prognosis in human malignancy.
J Clin Oncol. 5:1690–1703. 1987.PubMed/NCBI
|
|
57
|
Clark GM, Mathieu M-C, Owens MA, et al:
Prognostic significance of S-phase fraction in good-risk,
node-negative breast cancer patients. J Clin Oncol. 10:428–432.
1992.PubMed/NCBI
|
|
58
|
Fernandez EB, Sesterhenn IA, McCarthy WF,
et al: Proliferating cellnuclear antigen expression to predict
occult disease in clinical stage Inonseminomatous testicular germ
cell tumors. J Urol. 152:1133–1138. 1994.PubMed/NCBI
|
|
59
|
de Aguiar PH, Aires R, Laws ER, et al:
Labeling index in pituitary adenomas evaluated by means of MIB-1:
is there a prognostic role?. A critical review. Neurol Res.
32:1060–1071. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Prayson RA: The utility of MIB-1/Ki-67
immunostaining in the evaluation of central nervous system
neoplasms. Adv Anat Pathol. 12:144–148. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lind-Landström T, Habberstad AH, Sundstrøm
S and Torp SH: Prognostic value of histological features in diffuse
astrocytomas WHO grade II. Int J Clin Exp Pathol. 5:152–158.
2012.PubMed/NCBI
|
|
62
|
Nabi U, Nagi AH and Sami W: Ki-67
proliferating index and histological grade, type and stage of
colorectal carcinoma. J Ayub Med Coll Abbottabad. 20(4): 44–8.
2008.PubMed/NCBI
|
|
63
|
Hegazy A, Daoud SA and Ibrahim WS: Role of
Ki-67, P53 and Bcl-2 in Advanced Colorectal Carcinoma. Academic
Journal of Cancer Research. 7(3): 168–172. 2014.
|
|
64
|
Inwald EC, Klinkhammer-Schalke M and
Hofstädter F: Ki-67 is a prognostic parameter in breast cancer
patients: results of a large population-based cohort of a cancer
registry. Breast Cancer Res Treat. 139(2): 539–52. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Klöppel G, Perren A and Heiitz PU: The
gastroenteropancreatic neuroendocrine cell system and its tumors:
The WHO classification. Ann NY Acad Sci. 1014:13–27. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Morimoto R, Satoh F, Murakami O, et al:
Immunohistochemistry of a proliferation marker Ki67/MIB1 in
adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor
for recurrence of adrenocortical carcinomas. Endocr J. 55:49–55.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Gupta N, Srinivasan R and Rajwanshi A:
Functional biomarkers in cervical precancer: an overview. Diagn
Cytopathol. 38:618–623. 2010.
|
|
68
|
Jalava P, Kuopio T, Juntti-Patinen L, et
al: Ki67 immunohistochemistry: a valuable marker in prognostication
but with a risk of misclassification: proliferation subgroups
formed based on Ki67 immunoreactivity and standardized mitotic
index. Histopathology. 48:674–682. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhang B: Neoadjuvant endocrine therapy for
postmenopausal estrogen receptor-positive patients with breast
cancer. Zhonghua Zhong Liu Za Zhi. 33:241–244. 2011.(In Chinese).
PubMed/NCBI
|
|
70
|
Gentile V, Vicini P, Giacomelli L, et al:
Detection of human papillomavirus DNA, p53 and ki-67 expression in
penile carcinomas. Int J Immunopathol Pharmacol. 19:209–215.
2006.PubMed/NCBI
|
|
71
|
Kroeze SG, Bijenhof AM, Bosch JL and Jans
JJ: Diagnostic and prognostic tissuemarkers in clear cell and
papillary renal cell carcinoma. Cancer Biomark. 7:261–268.
2010.PubMed/NCBI
|
|
72
|
D’Angelo E and Prat J: Uterine sarcomas: a
review. Gynecol Oncol. 116:131–139. 2010. View Article : Google Scholar
|
|
73
|
Yu JY, DeRuiter SL and Turner DL: RNA
interference by expression of short-interfering RNAs and hairpin
RNAs in mammalian cells. Proc Natl Acad Sci USA. 99:6047–6052.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Li L, Thomas RM, Suzuki H, et al: A small
molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell
death. Science. 305:1471–1474. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ben-Izhak O, Bar-Chana M, Sussman L, et
al: Ki67 antigen and PCNA proliferation markers predict survival in
anorectal malignant melanoma. Histopathology. 41:519–525. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Hu HY, Liu H, Zhang JW, et al: Clinical
significance of Smac and Ki-67 expression in pancreatic cancer.
Hepatogastroenterology. 59:2640–2643. 2012.PubMed/NCBI
|
|
77
|
Liu YZ, Jiang YY, Hao JJ, et al:
Prognostic significance of MCM7 expression in the bronchial
brushings of patients with non-small cell lung cancer (NSCLC). Lung
Cancer. 77:176–182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Golmohammadi R and Pejhan A: The
prognostic value of the P53 protein and the Ki67 marker in breast
cancer patients. J Pak Med Assoc. 62:871–875. 2012.PubMed/NCBI
|
|
79
|
Tihan T, Davis R, Elowitz E, et al:
Practical value of Ki-67 and p53 labeling indexes in stereotactic
biopsies of diffuse and pilocytic astrocytomas. Arch Pathol Lab
Med. 124:108–113. 2000.PubMed/NCBI
|
|
80
|
Iamaroon A, Khemaleelakul U, Pongsiriwet S
and Pintong J: Co-expression of p53 and Ki67 and lack of EBV
expression in oral squamous cell carcinoma. J Oral Pathol Med.
33:30–36. 2004. View Article : Google Scholar
|
|
81
|
Boonyaphiphat P, Pruegsanusak K and
Thongsuksai P: The prognostic value of p53, Bcl-2 and Bax
expression in laryngeal cancer. J Med Assoc Thai. 95:1317–1320.
2012.PubMed/NCBI
|
|
82
|
Tadbir AA, Pardis S, Ashkavandi ZJ, et al:
Expression of Ki67 and CD105 as proliferation and angiogenesis
markers in salivary gland tumors. Asian Pac J Cancer Prev.
13:5155–5159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Chen JX, Deng N, Chen X, et al: A novel
molecular grading model: combination of Ki67 and VEGF in predicting
tumor recurrence and progression in non-invasive urothelial bladder
cancer. Asian Pac J Cancer Prev. 13:2229–2234. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Hoogerbrugge N, Hermens RP, Nagengast F,
et al: Tumour examination to detect hereditary colorectal cancer.
Ned Tijdschr Geneeskd. 156:A49822012.(In Dutch).
|
|
85
|
Nabi U, Nagi AH and Sami W: Ki-67
proliferating index and histological grade, type and stage of
colorectal carcinoma. J Ayub Med Coll Abbottabad. 20:44–48.
2008.PubMed/NCBI
|
|
86
|
Tvedskov TF: Staging of women with breast
cancer after introduction of sentinel node guided axillary
dissection. Dan Med J. 59:B44752012.PubMed/NCBI
|
|
87
|
Wang MJ, Pei DS, Qian GW, et al: p53
regulates Ki-67 promoter activity through p53-and Sp1-dependent
manner in HeLa cells. Tumour Biol. 32:905–912. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Grala B, Markiewicz T, Kozowski W, et al:
New automated image analysis method for the assessment of Ki-67
labeling index in meningiomas. Folia Histochem Cytobiol.
47:587–592. 2009.PubMed/NCBI
|
|
89
|
Tuominen VJ, Ruotoistenmäki S, Viitanen A,
et al: ImmunoRatio: a publicly available web application for
quantitative image analysis of estrogen receptor (ER), progesterone
receptor (PR), and Ki-67. Breast Cancer Res. 12:R562010. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Gilles FH, Tavaré CJ, Becker LE, et al:
Pathologist interobserver variability of histologic features in
childhood brain tumors: results from the CCG-945 study. Pediatr Dev
Pathol. 11:108–117. 2008. View Article : Google Scholar
|
|
91
|
Grzybicki DM, Liu Y, Moore SA, et al:
Interobserver variability associated with the MIB-1 labeling index:
high levels suggest limited prognostic usefulness for patients with
primary brain tumors. Cancer. 92:2720–2726. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Hsu CY, Ho DM, Yang CF and Chiang H:
Interobserver reproducibility of MIB-1 labeling index in astrocytic
tumors using different counting methods. Mod Pathol. 16:951–957.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Walker RA: Quantification of
immunohistochemistry - issues concerning methods, utility and
semiquantitative assessment I. Histopathology. 49:406–410. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Bertucci F, Finetti P, Roche H, et al:
Comparison of the prognostic value of genomic grade index, Ki67
expression and mitotic activity index in early node-positive breast
cancer patients. Ann Oncol. 24:625–632. 2013. View Article : Google Scholar
|
|
95
|
Nielsen PS, Riber-Hansen R, Raundahl J and
Steiniche T: Automated quantification of MART1-verified Ki67
indices by digital image analysis in melanocytic lesions. Arch
Pathol Lab Med. 136:627–634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Nielsen PS, Riber-Hansen R and Steiniche
T: Immunohistochemical double stains against Ki67/MART1 and
HMB45/MITF: promising diagnostic tools in melanocytic lesions. Am J
Dermatopathol. 33:361–370. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Petit T, Wilt M, Velten M, et al:
Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2
and topoisomerase II alpha status as predictive markers in breast
cancer patients treated with neoadjuvant anthracycline-based
chemotherapy. Eur J Cancer. 40:205–211. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Chang J, Ormerod M, Powles TJ, et al:
Apoptosis and proliferation as predictors of chemotherapy response
in patients with breast carcinoma. Cancer. 89:2145–2152. 2000.
View Article : Google Scholar
|
|
99
|
Viale G, Giobbie-Hurder A, Regan MM, et
al: Prognostic and predictive value of centrally reviewed Ki-67
labeling index in postmenopausal women with endocrine-responsive
breast cancer: results from Breast International Group Trial 1–98
comparing adjuvant tamoxifen with letrozole. J Clin Oncol.
26:5569–75. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Yerushalmi R, Woods R, Ravdin PM, et al:
Ki67 in breast cancer: prognostic and predictive potential. Lancet
Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Park JY, Kim KR and Nam JH:
Immunohistochemical analysis for therapeutic targets and prognostic
markers in low-grade endometrial stromal sarcoma. Int J Gynecol
Cancer. 23:81–89. 2013. View Article : Google Scholar
|
|
102
|
Nagao K, Yamamoto Y, Hara T, et al: Ki67
and BUBR1 may discriminate clinically insignificant prostate cancer
in the PSA range <4 ng/ml. Jpn J Clin Oncol. 41:555–564. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Machowska M, Wachowicz K, Sopel M, et al:
Nuclear location of tumor suppressor protein maspin inhibits
proliferation of breast cancer cells without affecting
proliferation of normal epithelial cells. BMC Cancer. 14:1422014.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Nielsen PS, Riber-Hansen R, Jensen TO, et
al: Proliferation indices of phosphor-histone H3 and Ki67: strong
prognostic markers in a consecutive cohort with stage I/II
melanoma. Mod Pathol. 26(3): 404–13. 2013. View Article : Google Scholar
|
|
105
|
Vogt N and Klapper W: Variability in
morphology and cell proliferation in sequential biopsies of mantle
cell lymphoma at diagnosis and relapse: clinical correlation and
insights into disease progression. Histopathology. 62:334–342.
2013. View Article : Google Scholar
|
|
106
|
Palmqvist R, Sellberg P, Oberg A, et al:
Low tumour cell proliferation at the invasive marginis associated
with a poor prognosis in Dukes’ stage B colorectal cancers. Br J
Cancer. 79:577–581. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Kimura T, Tanaka S, Haruma K, et al:
Clinical significance of MUC1 and E-cadherin expression, cellular
proliferation, and angiogenesis at the deepest invasive portion of
colorectal cancer. Int J Oncol. 16:55–64. 2000.
|
|
108
|
Holdcraft J and Gallagher JC: Malignant
melanomas of the nasal and paranasal sinus mucosa. Ann Otol Rhinol
Laryngol. 78:5–20. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Rinaldo A, Shaha AR, Patel SG and Ferlito
A: Primary mucosal melanoma of the nasal cavity and paranasal
sinuses. Acta Otolaryngol. 121:979–982. 2001. View Article : Google Scholar
|
|
110
|
Bisgaard ML: Young age colorectal cancer
and identification of hereditary non-polyposis colorectal cancer
cohorts. Br J Surg. 94:1055–1056. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Niezabitowski A, Czajecki K, Ryś J, et al:
Prognostic evaluation of cutaneous malignant melanoma: a
clinicopathologic and immunohistochemical study. J Surg Oncol.
70:150–160. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Tuleta I, Bauriedel G, Steinmetz M, et al:
Apoptosis-regulated survival of primarily extravascular cells in
proliferative active poststent neointima. Cardiovasc Pathol.
19:353–360. 2010. View Article : Google Scholar
|
|
113
|
Wajed SA, Laird PW and DeMeester TR: DNA
methylation: an alternative pathway to cancer. Ann Surg. 234:10–20.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Zheng JN, Ma TX, Cao JY, et al: Knockdown
of Ki-67 by small interfering RNA leads to inhibition of
proliferation and induction of apoptosis in human renal carcinoma
cells. Life Sci. 78:724–729. 2006. View Article : Google Scholar
|
|
115
|
Zheng JN, Sun YF, Pei DS, et al:
Anti-Ki-67 peptide nucleic acid affects the proliferation and
apoptosis of human renal carcinoma cells in vitro. Life Sci.
76:1873–1881. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Chan JH, Lim S and Wong WS: Antisense
oligonucleotides: from design to therapeutic application. Clin Exp
Pharmacol Physiol. 33:533–540. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Paulasova P and Pellestor F: The peptide
nucleic acids (PNAs): a new generation of probes for genetic and
cytogenetic analyses. Ann Genet. 47:349–358. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Smolina IV and Demidov VV:
Sequence-universal recognition of duplex DNA by oligonucleotides
via pseudocomplementarity and helix invasion. Chem Biol.
10:591–595. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Demidov VV and Frank-Kamenetskii MD: Two
sides of the coin: affinity and specificity of nucleic acid
interactions. Trends Biochem Sci. 29:62–71. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Demidov VV, Potaman VN, Frank-Kamenetskii
MD, et al: Stability of peptide nucleic acids in human serum and
cellular extracts. Biochem Pharmacol. 48:1310–1313. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Tuschl T: RNA interference and small
interfering RNAs. Chembiochem. 2:239–245. 2001. View Article : Google Scholar
|
|
122
|
Zheng JN, Pei DS, Mao LJ, et al:
Inhibition of renal cancer cell growth in vitro and in vivo with
oncolytic adenovirus armed short hairpin RNA targeting Ki-67
encoding mRNA. Cancer Gene Ther. 16:20–32. 2009. View Article : Google Scholar
|
|
123
|
Pai SI, Lin YY, Macaes B, Meneshian A,
Hung CF and Wu TC: Prospects of RNA interference therapy for
cancer. Gene Ther. 13:464–477. 2006. View Article : Google Scholar
|
|
124
|
Brummelkamp TR, Bernards R and Agami R: A
system for stable expression of short interfering RNAs in mammalian
cells. Science. 296:550–553. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Lieberman J, Song E, Lee SK and Shankar P:
Interfering with disease: opportunities and roadblocks to
harnessing RNA interference. Trends Mol Med. 9:397–403. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Moore CB, Guthrie EH, Huang MT and Taxman
DJ: Short hairpin RNA (shRNA): design, delivery, and assessment of
gene knockdown. Methods Mol Biol. 629:141–158. 2010.PubMed/NCBI
|
|
127
|
Zhu H, Guo W, Zhang L, et al: Bcl-XL small
interfering RNA suppresses the proliferation of
5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther.
4:451–456. 2005.PubMed/NCBI
|
|
128
|
Starborg M, Gell K, Brundell E and Höög C:
The murine Ki-67 cell proliferation antigen accumulates in the
nucleolar and heterochromatic regions of interphase cells and at
the periphery of the mitotic chromosomes in a process essential for
cell cycle progression. J Cell Sci. 109:143–153. 1996.PubMed/NCBI
|
|
129
|
Zhang P, Steelant W, Kumar M and
Scholfield M: Versatile photosensitizers for photodynamic therapy
at infrared excitation. J Am Chem Soc. 129:4526–4527. 2007.
View Article : Google Scholar : PubMed/NCBI
|
